The Valley Desk

ArticleJTO clinical and research reportsPublished

Phase II Trial of Regorafenib and Oral Methotrexate in Previously Treated Advanced KRAS-Mutant NSCLC

Read the publication ↗ Open access copy ↗

Regional connection

Verified Author affiliations on the Europe PMC record name Fox Chase Cancer Center, Temple Health. Affiliation source

Publication record

Type
Article
Venue
JTO clinical and research reports
Published
Subject terms
Methotrexate; ctDNA; Targeted Therapy; Kras Mutation; Regorafenib
PubMed ID
39624248
PubMed Central ID
PMC11609302
Open access
Yes, open
Added to directory
Source checked

Report a correction or request removal